Therealreal, Inc. current report, 16 June 2020

Business Context and Reporting Period

This Form 8-K filing by The RealReal, Inc. (REAL) covers events occurring on June 16, 2020, with the report dated June 22, 2020. The filing addresses corporate governance matters, specifically a temporary non-compliance with Nasdaq listing rules regarding audit committee composition and the results of the 2020 Annual Meeting of Stockholders.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.

Material Changes and Corporate Events

  • Audit Committee Vacancy: The Company notified Nasdaq of non-compliance with Listing Rule 5605(c)(2)(A) due to a vacancy on the audit committee following the departure of Maha Ibrahim from the Board of Directors after the Annual Meeting.
  • Cure Period: On June 19, 2020, Nasdaq confirmed a cure period applicable to the Company to regain compliance. The Company intends to resolve the vacancy within this timeframe.
  • Board Composition: Rob Krolik and James Miller continue to serve on the audit committee.

Annual Meeting Results and Management Commentary

The Company held its Annual Meeting on June 16, 2020, to vote on two proposals:

  • Proposal 1 (Election of Class I Director): Michael Kumin was elected.
    • For: 56,512,371 votes
    • Withhold: 3,177,009 votes
    • Broker Non-Votes: 13,194,451 votes
  • Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
    • For: 72,779,918 votes
    • Against: 61,039 votes
    • Abstain: 42,874 votes

Investor Verification Checklist

  • Verify the timeline for filling the audit committee vacancy to ensure compliance with the Nasdaq cure period.
  • Confirm the final composition of the Board of Directors and audit committee in subsequent filings.
  • Review the definitive proxy statement for detailed background on the director nominee and auditor ratification.